Weiss Multi Strategy Advisers LLC Relmada Therapeutics, Inc. Transaction History

Weiss Multi Strategy Advisers LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$16.5 - $30.34 $371,250 - $682,650	22,500 Added 300.0%	30,000 $570,000
Q1 2022 May 16, 2022	BUY	$16.72 - $26.99 $125,399 - $202,425	7,500 New	7,500 $202,000
Q3 2021 Nov 15, 2021	SELL	$21.86 - $34.77 $153,959 - $244,885	-7,043 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$29.55 - $39.15 $208,120 - $275,733	7,043 New	7,043 $225,000
Q1 2021 May 14, 2021	SELL	$31.52 - $39.28 $265,839 - $331,287	-8,434 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$29.88 - $39.8 $12,967 - $17,273	434 Added 5.43%	8,434 $270,000
Q3 2020 Nov 16, 2020	BUY	$34.42 - $43.78 $275,360 - $350,240	8,000 New	8,000 $301,000
Q2 2020 Aug 14, 2020	SELL	$31.59 - $49.98 $291,417 - $461,065	-9,225 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$23.78 - $50.12 $89,769 - $189,203	-3,775 Reduced 29.04%	9,225 $315,000
Q4 2019 Feb 14, 2020	BUY	$10.1 - $47.18 $131,300 - $613,340	13,000 New	13,000 $507,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $11.7M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.